Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Abstract Background The two 52-week INPULSIS trials investigated nintedanib versus placebo in patients with IPF, FVC ≥50% predicted and DLco 30–79% predicted. The 24-week INSTAGE trial investigated nintedanib plus sildenafil versus nintedanib alone in patients with IPF and DLco ≤35% predicted. We us...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Luca Richeldi, Martin Kolb, Stéphane Jouneau, Wim A. Wuyts, Birgit Schinzel, Susanne Stowasser, Manuel Quaresma, Ganesh Raghu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2020-01-01
Serie:	BMC Pulmonary Medicine
Soggetti:	Clinical trial Interstitial lung diseases Tyrosine kinase inhibitor Vital capacity
Accesso online:	https://doi.org/10.1186/s12890-019-1030-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!